Fast track — ArticlesAngiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials
Introduction
Antagonists of the angiotensin II type-1 receptor (ie, angiotensin-receptor blockers, ARBs) are a widely used class of drugs. The first ARB, losartan, was approved for clinical use in 1995, followed by six other drugs, including valsartan, candesartan, irbesartan, telmisartan, olmesartan, and eprosartan. These drugs are used for treatment of highly prevalent conditions such as hypertension, heart failure, and diabetic nephropathy.1, 2, 3 Most recently, telmisartan was approved for lowering the risk of cardiovascular events in high-risk patients who are unable to take angiotensin-converting enzyme (ACE) inhibitors. Many large, randomised controlled trials of ARBs have supported their clinical indications.4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
Currently, there are no major safety concerns with ARBs, apart from their use in pregnancy, renal-artery stenosis, and chronic kidney disease. Although preclinical carcinogenicity studies in rats and mice have been negative,24, 25, 26 experimental studies implicate the renin-angiotensin system, particularly angiotensin II type-1 and type-2 receptors (AT1R and AT2R), in the regulation of cellular proliferation, angiogenesis, and tumour progression.27 However, clinical trials of ARBs have mainly assessed their effects on cardiovascular and renal endpoints and have usually not reported incidence of cancers. In 2003, the Candesartan in Heart failure Assessment of Reduction in Mortality and Morbidity (CHARM) programme, assessing ARBs in heart failure, reported an unexpected finding of significantly higher fatal cancers in the candesartan group than with placebo.5 Because the results of several other large ARB trials have become available since the publication of the CHARM trial, we decided to do a meta-analysis of randomised controlled trials of these drugs, to examine their effect on occurrence of new cancers. Our secondary objectives were to determine whether ARBs affect the occurrence of specific solid-organ cancers and cancer deaths.
Section snippets
Data collection
The aim of this meta-analysis was to include all publicly available data for development of cancers from randomised controlled trials of ARBs. We did systematic searches of Medline, Scopus (including Embase and several other journal groups from a wide range of disciplines), Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and the public website of the US Food and Drug Administration (FDA), through November, 2009. The search terms and other search
Results
Characteristics of the randomised controlled trials included in the analyses are summarised in table 1. Both patients and investigators were masked to treatment allocation in all trials. For the primary outcome of cancer occurrence, telmisartan was the main ARB used as the study drug (in 30 014 [85·7%] patients). There was no notable imbalance within trial groups with regard to age, sex, ethnic origin, smoking status, and history of previous cancer. Overall, very few patients had a history of
Discussion
In this meta-analysis, we found that ARBs are associated with a modestly increased risk of new cancer occurrence. To the best of our knowledge, this analysis incorporated all publicly available data on new cancer occurrence from randomised trials of ARBs. Information was from peer-reviewed publications and data posted on the FDA website, a valuable source for meta-analyses.44 A strength of this meta-analysis is the inclusion of data from randomised controlled trials only, thereby reducing the
References (48)
- et al.
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
Lancet
(2002) - et al.
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
Lancet
(2003) - et al.
Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials
Lancet
(2008) - et al.
Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan
Lancet
(2002) - et al.
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial
Lancet
(2004) - et al.
Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study
Lancet
(2007) - et al.
Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial
Lancet
(2008) - et al.
Angiotensin receptors: a new role in cancer?
Trends Endocrinol Metab
(2005) - et al.
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial
Lancet
(2003) - et al.
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial
Lancet
(2003)
The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report
JAMA
ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society
Circulation
Diabetes Care
Feasibility of treating prehypertension with an angiotensin-receptor blocker
N Engl J Med
Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial
Lancet
Telmisartan, ramipril, or both in patients at high risk for vascular events
N Engl J Med
Telmisartan to prevent recurrent stroke and cardiovascular events
N Engl J Med
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
N Engl J Med
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
N Engl J Med
Irbesartan in patients with heart failure and preserved ejection fraction
N Engl J Med
Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial
Hypertension
The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial
J Hypertens
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
N Engl J Med
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both
N Engl J Med
Cited by (426)
Evolving perspectives in reverse cardio-oncology: A review of current status, pathophysiological insights, and future directives
2024, Current Problems in CardiologyLosartan alleviates renal fibrosis by inhibiting the biomechanical stress-induced epithelial-mesenchymal transition of renal epithelial cells
2023, Archives of Biochemistry and BiophysicsRepurposing drugs targeting metabolic diseases for cancer therapeutics
2023, Drug Discovery TodayAngiotensin-converting enzyme
2023, Metalloenzymes: From Bench to BedsideSeveral first-line anti-hypertensives act on fibrosarcoma progression and PD1ab blockade therapy
2024, Journal of Orthopaedic Surgery and ResearchAssociation between hypertension grades and cancer mortality among Japanese men and women
2024, Cancer Causes and Control